Rare Disease

In the first activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety considerations, and efficacy data of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for FcRn antagonist therapy, and apply an individualized approach to treatment planning based on available evidence and patient preferences.

In the second activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety, and efficacy profiles of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists, and utilize an individualized approach to treatment planning for patients with gMG receiving FcRn antagonists based on the latest data as well as patient preferences.

In this CME Outfitters Grand Rounds activity, international expert faculty will guide participants through a discussion of the guideline-recommended tools and measures to facilitate early and accurate diagnosis of CIDP, how to utilize real-world strategies to implement novel Ig-targeted therapies in diverse practice settings, and how to implement collaborative care to improve long-term management of CIDP.

Immunoglobulin A nephropathy (IgAN) is a progressive glomerular disease and a leading cause of chronic kidney disease (CKD), with up to 40% of patients advancing to kidney failure within two decades. Despite guideline-recommended management emphasizing supportive care and RAAS inhibition, many patients continue to experience persistent proteinuria and declining renal function. Clinical practice remains inconsistent, particularly regarding the use of assessment tools and initiation of immunosuppressive therapies. While updated risk scoring models, AI-driven risk stratification tools, and biomarker-guided assessments have emerged, awareness and utilization in routine care are limited. As new therapies enter practice, clinicians require practical education to incorporate evolving evidence into patient care. To meet this need, a virtual journal club series will deliver concise, case-based learning that translates recent clinical trial findings into actionable strategies. This format is designed to foster reflection, support informed decision-making, and help nephrologists and other HCPs optimize treatment pathways for patients living with IgAN.

This CMEO Journal Club will equip HCPs with the latest evidence from recent clinical trials and scientific literature, enabling them to evaluate new prophylactic strategies and incorporate non-factor therapies into comprehensive, individualized treatment plans. Expert faculty will translate data into real-world insights to support improved patient outcomes and long-term disease management.

In this  CME Outfitters recorded symposium, leading experts will explore:

✅ Early, guideline-based diagnosis  to improve patient outcomes
✅ The latest efficacy and safety data  on current and emerging therapies, including oral treatments
✅ Individualized care strategies  that consider patient needs, comorbidities, and barriers to adherence

Stay ahead of the curve with cutting-edge insights  to enhance patient care and optimize long-term management of acromegaly.

In this CME Outfitters Snack, expert faculty will assess the various presentations of PI, including atypical presentations, to improve PI recognition and diagnosis. Faculty will differentiate among the immunoglobulin therapies available for the treatment of PI that enable optimal, personalized care as well as demonstrate how to develop multidisciplinary, team-based strategies to address disparities in care among patients with PI.

In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.

In this CMEO recorded webcast, expert faculty will present and discuss advances in non-factor therapies for hemophilia, including advancements in laboratory and monitoring practices and how to use shared decision-making (SDM) with patients to design individualized care plans that incorporate non-factor replacement therapies into treatment.